ZOSTAVAX [ ZOSTER VACCINE LIVE (OKA/MERCK), MSD] मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zostavax [ zoster vaccine live (oka/merck), msd]

merck sharp & dohme (malaysia) sdn bhd - zoster vaccine live oka/merck -

ZOSTAVAX (ZOSTER VACCINE LIVE) इसराइल - अंग्रेज़ी - Ministry of Health

zostavax (zoster vaccine live)

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

MSD-ERTUGLIFLOZIN-SITAGLIPTIN 5/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 5 mg/100 mg film-coated tablet blister ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-sitagliptin 5/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 5 mg/100 mg film-coated tablet blister

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg); ertugliflozin pyroglutamic acid, quantity: 6.48 mg (equivalent: ertugliflozin, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; sodium stearylfumarate; microcrystalline cellulose; calcium hydrogen phosphate; carnauba wax; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - msd-ertugliflozin-sitagliptin (ertugliflozin and sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials, and 4.4 special warnings and precautions for use]

MSD-ERTUGLIFLOZIN-SITAGLIPTIN 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet bliste ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-sitagliptin 15/100 ertugliflozin/sitagliptin (as phosphate monohydrate) 15 mg/100 mg film-coated tablet bliste

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 128.5 mg (equivalent: sitagliptin, qty 100 mg); ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium stearylfumarate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; carnauba wax; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - msd-ertugliflozin-sitagliptin (ertugliflozin and sitagliptin phosphate monohydrate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials, and 4.4 special warnings and precautions for use]

MSD-ERTUGLIFLOZIN-METFORMIN 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 7.5/500 ertugliflozin/metformin hydrochloride 7.5 mg/500 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: crospovidone; sodium lauryl sulfate; microcrystalline cellulose; carnauba wax; povidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 2.5/500 ertugliflozin/metformin hydrochloride 2.5 mg/500 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 500 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; carnauba wax; povidone; sodium lauryl sulfate; magnesium stearate; crospovidone; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 7.5/1000 ertugliflozin/metformin hydrochloride 7.5 mg/1000 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 9.713 mg (equivalent: ertugliflozin, qty 7.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; povidone; magnesium stearate; crospovidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN-METFORMIN 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin-metformin 2.5/1000 ertugliflozin/metformin hydrochloride 2.5 mg/1000 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 1000 mg; ertugliflozin pyroglutamic acid, quantity: 3.238 mg (equivalent: ertugliflozin, qty 2.5 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; crospovidone; magnesium stearate; povidone; carnauba wax; microcrystalline cellulose; titanium dioxide; hypromellose; hyprolose; iron oxide red - msd-ertugliflozin-metformin (ertugliflozin and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and metformin is appropriate. [see 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration]

MSD-ERTUGLIFLOZIN 5 ertugliflozin 5 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin 5 ertugliflozin 5 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 6.48 mg (equivalent: ertugliflozin, qty 5 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - msd-ertugliflozin (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].

MSD-ERTUGLIFLOZIN 15 ertugliflozin 15 mg film-coated tablet blister pack ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

msd-ertugliflozin 15 ertugliflozin 15 mg film-coated tablet blister pack

merck sharp & dohme (australia) pty ltd - ertugliflozin pyroglutamic acid, quantity: 19.43 mg (equivalent: ertugliflozin, qty 15 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red; macrogol 3350 - msd-ertugliflozin (ertugliflozin) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:- - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents,[see 5.1 pharmacodynamic properties, clinical trials and 4.4 special warnings and precautions for use for available data on different add-on combination therapies].